$474.62
1.94% yesterday
Nasdaq, Apr 04, 10:09 pm CET
ISIN
US92532F1003
Symbol
VRTX
Sector
Industry

Vertex Pharmaceuticals Target price 2025 - Analyst rating & recommendation

Vertex Pharmaceuticals Classifications & Recommendation:

Buy
57%
Hold
37%
Sell
6%

Vertex Pharmaceuticals Price Target

Target Price $506.92
Price $474.62
Potential 6.81%
Number of Estimates 26
26 Analysts have issued a price target Vertex Pharmaceuticals 2026 . The average Vertex Pharmaceuticals target price is $506.92. This is 6.81% higher than the current stock price. The highest price target is $615.00 29.58% , the lowest is $330.00 30.47% .
A rating was issued by 35 analysts: 20 Analysts recommend Vertex Pharmaceuticals to buy, 13 to hold and 2 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Vertex Pharmaceuticals stock has an average upside potential 2026 of 6.81% . Most analysts recommend the Vertex Pharmaceuticals stock at Purchase.

Sales and Margin forecast 2025, 2026 to 2029


Dec '24 2025
Estimates
Revenue Billion $ 10.98 11.97
11.64% 8.99%
EBITDA Margin 41.56% 46.44%
8.29% 11.74%
Net Margin -4.87% 34.53%
113.41% 809.70%

28 Analysts have issued a sales forecast Vertex Pharmaceuticals 2025 . The average Vertex Pharmaceuticals sales estimate is $12.0b . This is 8.99% higher than the revenue of the last 12 months(TTM). The highest sales forecast is $12.5b 13.38% , the lowest is $11.8b 6.97% .

This results in the following potential growth metrics:

Revenue Estimates

2024 $11.0b 11.64%
2025 $12.0b 8.99%
2026 $13.2b 9.89%
2027 $14.3b 8.95%
2028 $15.5b 8.33%
2029 $17.2b 10.80%

8 Analysts have issued an Vertex Pharmaceuticals EBITDA forecast 2025. The average Vertex Pharmaceuticals EBITDA estimate is $5.6b . This is 22,876.47% higher than the EBITDA of the last 12 months(TTM). The highest EBITDA forecast is $6.1b 24,966.71% , the lowest is $4.8b 19,847.65% .

This results in the following potential growth metrics and future EBITDA Margins:

EBITDA Estimates

2024 $4.6b 2.39%
2025 $5.6b 21.80%
2026 $6.8b 21.99%
2027 $7.5b 10.65%
2028 $8.2b 9.58%
2029 $9.1b 10.19%

EBITDA Margin

2024 41.56% 8.29%
2025 46.44% 11.74%
2026 51.56% 11.02%
2027 52.36% 1.55%
2028 52.96% 1.15%
2029 52.67% 0.55%

19 Vertex Pharmaceuticals Analysts have issued a net profit forecast 2025. The average Vertex Pharmaceuticals net profit estimate is $4.1b . This is 831.45% higher than the net profit for the last 12 months(TTM). The highest net profit forecast is $4.7b 927.27% , the lowest is $3.6b 734.55% .

This results in the following potential growth metrics and future Net Margins:

Net Profit Estimates

2024 $-534m 114.97%
2025 $4.1b 873.65%
2026 $4.8b 15.25%
2027 $5.2b 9.97%
2028 $6.3b 19.60%
2029 $6.8b 8.84%

Net Margin

2024 -4.87% 113.41%
2025 34.53% 809.70%
2026 36.22% 4.89%
2027 36.56% 0.94%
2028 40.36% 10.39%
2029 39.65% 1.76%

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029


Dec '24 2025
Estimates
Earnings Per Share $ -2.08 16.09
114.97% 873.56%
P/E 29.49
EV/Sales 9.82

19 Analysts have issued a Vertex Pharmaceuticals forecast for earnings per share. The average Vertex Pharmaceuticals EPS is $16.09 . This is 831.36% higher than earnings per share in the financial year 2024. The highest EPS forecast is $18.20 927.27% , the lowest is $13.96 734.55% .

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2024 $-2.08 114.97%
2025 $16.09 873.56%
2026 $18.55 15.29%
2027 $20.39 9.92%
2028 $24.39 19.62%
2029 $26.55 8.86%

P/E ratio

Current -215.57 816.42%
2025 29.49 113.68%
2026 25.59 13.22%
2027 23.27 9.07%
2028 19.46 16.37%
2029 17.88 8.12%

Based on analysts' sales estimates for 2025, the Vertex Pharmaceuticals stock is valued at an EV/Sales of 9.82 and an P/S ratio of 10.18 .

This results in the following potential growth metrics and future valuations:

EV/Sales

Current 10.70 7.86%
2025 9.82 8.27%
2026 8.93 9.00%
2027 8.20 8.22%
2028 7.57 7.69%
2029 6.83 9.74%

P/S ratio

Current 11.10 1.11%
2025 10.18 8.25%
2026 9.26 9.00%
2027 8.50 8.22%
2028 7.85 7.69%
2029 7.08 9.74%

Current Vertex Pharmaceuticals Upgrades & Downgrades

Analyst Rating Action Date
RBC Capital
Sector Perform
Sector Perform
Unchanged Apr 01 2025
B of A Securities
Buy
Buy
Unchanged Mar 31 2025
RBC Capital
Sector Perform
Sector Perform
Unchanged Feb 20 2025
Canaccord Genuity
Sell
Hold
Upgrade Feb 12 2025
Barclays
Equal-Weight
Equal-Weight
Unchanged Feb 11 2025
HC Wainwright & Co.
Buy
Buy
Unchanged Feb 11 2025
Needham
Hold
Hold
Unchanged Feb 11 2025
Analyst Rating Date
Unchanged
RBC Capital:
Sector Perform
Sector Perform
Apr 01 2025
Unchanged
B of A Securities:
Buy
Buy
Mar 31 2025
Unchanged
RBC Capital:
Sector Perform
Sector Perform
Feb 20 2025
Upgrade
Canaccord Genuity:
Sell
Hold
Feb 12 2025
Unchanged
Barclays:
Equal-Weight
Equal-Weight
Feb 11 2025
Unchanged
HC Wainwright & Co.:
Buy
Buy
Feb 11 2025
Unchanged
Needham:
Hold
Hold
Feb 11 2025

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today